Jane Street’s Kezar Life Sciences KZR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-21,367
| Closed | -$159K | – | 12434 |
|
|
2026
Q1 | $159K | Buy |
+21,367
| New | +$139K | ﹤0.01% | 10342 |
|
|
2024
Q4 | – | Sell |
-5,954
| Closed | -$46K | – | 10042 |
|
|
2024
Q3 | $46K | Sell |
5,954
-48,952
| -89% | -$295K | ﹤0.01% | 9193 |
|
|
2024
Q2 | $329K | Buy |
54,906
+52,449
| +2,135% | +$399K | ﹤0.01% | 7663 |
|
|
2024
Q1 | $22.2K | Sell |
2,457
-4,486
| -65% | -$40.9K | ﹤0.01% | 8889 |
|
|
2023
Q4 | $65.8K | Buy |
+6,943
| New | +$61K | ﹤0.01% | 8705 |
|
|
2023
Q3 | – | Sell |
-16,991
| Closed | -$416K | – | 9044 |
|
|
2023
Q2 | $416K | Buy |
16,991
+7,731
| +83% | +$201K | ﹤0.01% | 6599 |
|
|
2023
Q1 | $290K | Buy |
9,260
+7,728
| +504% | +$447K | ﹤0.01% | 7258 |
|
|
2022
Q4 | $108K | Sell |
1,532
-978
| -39% | -$72.5K | ﹤0.01% | 8050 |
|
|
2022
Q3 | $216K | Sell |
2,510
-7,106
| -74% | -$690K | ﹤0.01% | 8051 |
|
|
2022
Q2 | $795K | Buy |
9,616
+673
| +8% | +$59.4K | ﹤0.01% | 5904 |
|
|
2022
Q1 | $1.49M | Buy |
8,943
+5,822
| +187% | +$836K | ﹤0.01% | 5315 |
|
|
2021
Q4 | $522K | Buy |
+3,121
| New | +$352K | ﹤0.01% | 7181 |
|
|
2020
Q3 | – | Sell |
-2,278
| Closed | -$118K | – | 7569 |
|
|
2020
Q2 | $118K | Buy |
+2,278
| New | +$115K | ﹤0.01% | 6653 |
|
Jane Street's KZR Position: Q2 2026 in Review
Jane Street sold out of Kezar Life Sciences (KZR) in Q2 2026, closing a stake of 21,367 shares — an estimated $159K sold.
Jane Street first reported a position in KZR in Q2 2020 and held it in 13 quarters. The position peaked at $1.49M in Q1 2022. 0 funds tracked by Wall St. Rank hold KZR as of Q2 2026.
- Jane Street reported no remaining Kezar Life Sciences position as of Q2 2026 after selling out during the quarter.
- Jane Street sold 21,367 Kezar Life Sciences shares in Q2 2026, an estimated $159K.
- Jane Street first reported a position in Kezar Life Sciences in Q2 2020 and held it in 13 quarters.
- Jane Street's Kezar Life Sciences position peaked at $1.49M in Q1 2022.
- 0 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q2 2026.
Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.